Vanda Pharmaceuticals, a biopharmaceutical company, has entered into an exclusive license agreement with Argentina-based Biotoscana Farma, a wholly owned affiliate of Biotoscana International, based in Bogota, Colombia, for the commercialization of Fanapt in Argentina.
"We are very pleased to partner with Vanda in Argentina with Fanapt. Our recently submitted regulatory filing for marketing authorization for Fanapt marks the first step in the process towards the commercial launch of Fanapt in Argentina,” said Biotoscana's co-founder and CEO Ricardo Munoz Ridau.
Under the terms of the agreement, Biotoscana will seek regulatory approval for Fanapt in Argentina. Vanda will supply Biotoscana with Fanapt drug product for packaging and sale and Biotoscana's CNS specialty sales force will promote Fanapt to psychiatrists in Argentina.